Crossmark

: Eiji Shinozaki: Takeda Pharma, Merck, Lily, and Chugai Pharma. Yoshiaki Nakamura: Chugai Pharma, Guardant Health AMEA, and Merck Research Funding: Taiho Pharmaceutical (Inst), Guardant Health (Inst), Genomedia (Inst), Chugai Pharma (Inst), Guardant Health (Inst), Seattle Genetics (Inst), and Roche (Inst) Taito Esaki: Lilly, Taiho Pharmaceutical, Daiichi Sankyo, and Chugai Pharma Research Funding: Daiichi Sankyo (Inst), MSD (Inst), Novartis (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), Lilly (Inst), Bayer (Inst), Nihon Kayaku (Inst), Amgen Astellas BioPharma (Inst), Parexel (Inst), IQVIA (Inst), Quintiles (Inst), Eisai (Inst), Pfizer (Inst), Chugai Pharma (Inst), Syneos Health (Inst), Asahi Kasei Pharma (Inst), Amgen (Inst), Dainippon Sumitomo (Inst), and Dainippon Sumitomo (Inst) Hisateru Yasui: Taiho Pharmaceutical, Chugai Pharma, Bristol-Myers Squibb Japan, Daiichi Sankyo, Lilly, Yakult Honsha, Bayer Yakuhin, Takeda, and Ono Pharmaceutical Research Funding: MSD (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), and Daiichi Sankyo (Inst) Hiroya Taniguchi: Bayer, Sanofi, Takeda, Chugai Pharma, Taiho Pharmaceutical, Lilly, Merck Serono, Yakult Honsha, Medical & Biological Laboratories Co., Ltd, Bristol-Myers Squibb Japan, MSD K.K, Novartis, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Kayaku, and Ono Yakuhin Research Funding: Dainippon Sumitomo Pharma (Inst), Array BioPharma (Inst), MSD Oncology (Inst), Ono Pharmaceutical (Inst), Daiichi Sankyo (Inst), Sysmex (Inst), Novartis (Inst), and Takeda (Inst) Satake Hironaga: Bristol-Myers Squibb Co., Ltd., Bayer Co., Ltd., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd. and Yakult Honsha Co., Ltd. Research funding: Ono Pharmaceutical Co Ltd, Daiichi Sankyo, Taiho Pharmaceutical Co Ltd, and Takeda Pharmaceutical Co., Ltd. Yu Sunakawa: Taiho Pharmaceutical, Chugai Pharma, Takeda, Bayer Yakuhin, Bristol-Myers Squibb Japan, Lilly, Merck, Sysmex, MSD K.K, Ono Pharmaceutical, Daiichi Sankyo, Guardant Health, and Incyte Consulting or Advisory Role: Bristol-Myers Squibb Japan, MSD K.K, Daiichi Sankyo, and Merck Research Funding: Taiho Pharmaceutical, Takeda, Chugai Pharma, Lilly, Sanofi, and Otsuka Yoshito Komatsu: Lilly Japan, Taiho Pharmaceutical, Chugai Pharma, Takeda, Bayer Yakuhin, Bristol-Myers Squibb Co, Sanofi/Aventis, Merck, Yakult Honsha, Ono Pharmaceutical, Nipro Corporation, Moroo Co, Asahi Kasei, Mitsubishi Tanabe Pharma, Otsuka, Medical Review Co., Ltd, and Daiichi Sankyo Research Funding: MSD K.K, Taiho Pharmaceutical, Yakult Honsha, Bayer Yakuhin, DAIICHI SANKYO CO., Ltd, Ono Pharmaceutical, NanoCarrier, Eisai, Sanofi/Aventis, Sysmex, Shionogi, IQVIA, Parexel International Corporation, Astellas Pharma, Mediscience Planning, Sumitomo Dainippon Pharma Co., Ltd, A2 Healthcare, Incyte, Lilly (Inst), Nipro Corporation (Inst), and BeiGene (Inst) Yoshinori Kagawa. Consulting or Advisory Role: Taiho Pharmaceutical, Merck, and Lilly Speakers’ Bureau: Lilly, Sanofi, Takeda, Merck, Taiho Pharmaceutical, MSD, Chugai Pharma, Yakult Pharmaceutical, Bayer, and Ono Pharmaceutical. Research Funding: Ono Pharmaceutical Tadamichi Denda: Daiichi Sankyo and Ono Pharmaceutical, Sysmex. Research Funding: Ono Pharmaceutical (Inst), Amgen (Inst), MSD, Pfizer, and Bristol-Myers Squibb Foundation. Shiozawa Manabu: Lilly, Takeda, Taiho, Ono, Yakult, and Merck. Taroh Satoh: Chugai Pharma, Merck Serono, Bristol-Myers Squibb, Takeda, Yakult Honsha, Lilly, Bayer Yakuhin, Ono Pharmaceutical, Merck, Astellas Pharma, Taiho Pharmaceutical, Nihon Kayaku, and Daiichi Sankyo Consulting or Advisory Role: Bayer Yakuhin, Lilly, Ono Pharmaceutical, Takara Bio, Merck Serono, and Nihon Kayaku Research Funding: Yakult Honsha (Inst), Chugai Pharma (Inst), Ono Pharmaceutical (Inst), Sanofi (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Merck (Inst), Merck Serono (Inst), Gilead Sciences (Inst), Dainippon Sumitomo Pharma (Inst), and IQVIA (Inst) Tomohiro Nishina: Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Daiichi Sankyo, Chugai Pharma Research Funding: MSD (Inst), Ono Pharmaceutical (Inst), Astellas Pharma (Inst), Daiichi Sankyo/UCB Japan (Inst), Bristol-Myers Squibb Japan (Inst), Chugai Pharma (Inst), Taiho Pharmaceutical (Inst), and AstraZeneca (Inst). Masahiro Goto: Daiichi Sankyo Company, Limited, Ono Pharmaceutical, Taiho Pharmaceutical, MSD K.K, Takeda, Sumitomo Dainippon Pharma Co., Ltd, Yakult Pharmaceutical, and Lilly Research Funding: Chugai Pharma, Taiho Pharmaceutical, and Nippon Kayaku Naoki Takahashi: Ono Pharmaceutical, Bristol-Myers Squibb Japan, and Taiho Pharmaceutical Takeshi Kato: Chugai Pharma, Ono Pharmaceutical, Takeda, Lilly, and Asahi Kasei Research Funding: Chugai Pharma Hideaki Bando: Taiho, Lilly, and Ono. M.W. Nihon Medi-Physics. Research grant: Ono Pharmaceutical. Kensei Yamaguchi. Consulting or Advisory Role: Bristol-Myers Squibb Japan, and Daiichi Sankyo. Speakers’ Bureau: Chugai Pharma, Bristol-Myers Squibb Japan, Takeda, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, Daiichi Sankyo, and Merck Research Funding: Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Daiichi Sankyo (Inst), Lilly (Inst), Gilead Sciences (Inst), Yakult Honsha (Inst), Chugai Pharma (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), MSD Oncology (Inst), Sanofi (Inst), and Bristol-Myers Squibb (Inst) Takayuki Yoshino: Chugai Pharma, Takeda Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical, and MSD K.K. Consulting Fee: Sumitomo Corp. Research Funding: MSD (Inst), Daiichi Sankyo Company, Limited (Inst), Ono Pharmaceutical (Inst), Taiho Pharmaceutical (Inst), Amgen (Inst), Sanofi (Inst), Pfizer (Inst), Genomedia (Inst), Sysmex (Inst), Nippon Boehringer Ingelheim (Inst), Chugai Pharma (Inst), and Eisai (Inst). No other potential conflicts of interest were reported.

Document is current

Any future updates will be listed below